Cynosure Launches Next Generation Aesthetic Laser Device

PicoSure Pro device from Cynosure. [Image from Cynosure]

Cynosure today announced the launch of the PicoSure Pro device, its latest upgrade to the PicoSure platform.

PicoSure Pro, the first and only FDA cleared 755nm picosecond laser on the market, delivers energy in one billionth of a second, using pressure instead of heat to deliver safe and effective pigmentation treatments unwanted and skin revitalization for all skin types.

According to a press release, PicoSure Pro was designed with an advanced Platinum Focus lens matrix to increase collagen and elastin to help fight wrinkles, acne scars and pores. With the addition of a flat lens, Cynosure said, PicoSure Pro represents the first and only FDA-cleared picosecond laser for the treatment of pigment in melasma and other hyperpigmentation issues like Nevus of Ota. and Hori’s nevus.

Cynosure also said the system features enhancements such as a sleek, modern design, an intuitive graphical user interface, and a new 5mm handpiece ideal for treating inconspicuous lesions, lighter Fitzpatrick skin types, and areas smaller treatment.

“As the inventors of aesthetic picosecond laser technology, we constantly challenge ourselves to continuously drive innovation forward. Whether we are developing new devices or enhancing our trusted flagship products, we are focused on meeting the needs dissatisfied with our practitioners to ensure the best possible outcomes for their patients and their practice,” said Todd Tillemans, CEO of Cynosure. “From a 50% increase in energy to new handpieces and adjustable fluence, the performance enhancements to the PicoSure Pro device give practitioners more versatility than ever before, allowing them to effectively treat more patients a day and deliver better results in less time.”

Cynosure was formerly part of Hologic, following a $1.65 billion acquisition in March 2017. Hologic then sold the Cynosure business for approximately $205 million to a subsidiary of investment funds managed by Clayton, Dubilier & Rice in November 2019.


About Author

Comments are closed.